![Alex Tonks BSc (Hons), PhD, FHEA](https://profiles-cardiff.imgix.net/attachments/4119?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Alex Tonks
(e/fe)
BSc (Hons), PhD, FHEA
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Alex Tonks
Cyd-gyfarwyddwr yr Is-adran Canser a Geneteg
Trosolwyg
Rydw i ar hyn o bryd
Cyhoeddiad
2025
- Abdelfattah, A. et al. 2025. Impaired DNA damage responses and inflammatory signaling underpin hematopoietic stem cell defects in Gata2 haploinsufficiency. Stem Cell Reports 20(8), article number: 102596. (10.1016/j.stemcr.2025.102596)
2024
- Rizzo, S., Varache, M., Sayers, E. J., Jones, A. T., Tonks, A., Thomas, D. W. and Ferguson, E. L. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19, pp. 5419-5437. (10.2147/IJN.S449185)
- Sorouri Khorashad, J., Rizzo, S. and Tonks, A. 2024. Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia. Cancer Drug Resistance 7, article number: 5. (10.20517/cdr.2023.125)
2023
- Ullah, S. et al. 2023. Whole exome sequence of Pakistani acute lymphocytic leukemia patient from Pakhtuns ancestry reveal the novel genetic variant characterization in the GLDC gene. Journal of Biotechnology and Biomedicine 6(3), pp. 409-420. (10.26502/jbb.2642-91280103)
- Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37, pp. 276-287. (10.1038/s41375-022-01801-z)
- Wagstaff, M. et al. 2023. Crosstalk between β-catenin and WT1 signalling activity in acute myeloid leukemia [Letters to the Editor]. Haematologica 108(1) (10.3324/haematol.2021.280294)
2022
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132(21), article number: e150750. (10.1172/JCI150750)
- Menezes, A. C. et al. 2022. Increased expression of RUNX3 inhibits normal human myeloid development. Leukemia 36, pp. 1769-1780. (10.1038/s41375-022-01577-2)
- Ullah, S., Tonks, A., Ullah Khan, A., Alruwaili, A. M. and lodhi, M. A. 2022. A Case report of rare disease Prolidase deficiency in a 15-year-old Pakistan boy. Journal of Rare Diseases Research & Treatment 7(2), pp. 1-4. (10.29245/2572-9411/2022/2.1206)
- Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12, article number: 840046. (10.3389/fonc.2022.840046)
- Hillier, J. et al. 2022. The BCAT1 CXXC motif provides protection against ROS in acute myeloid leukaemia cells. Antioxidants 11(4), article number: 683. (10.3390/antiox11040683)
- Menezes, A. C. et al. 2022. RUNX3 overexpression inhibits normal human erythroid development. Scientific Reports 12, article number: 1243. (10.1038/s41598-022-05371-z)
2021
- Abdelfattah, A. M. et al. 2021. Gata2 haploinsufficiency promotes proliferation and functional decline of HSCs with myeloid bias during aging. Blood Advances 5(20), pp. 4285-4290. (10.1182/bloodadvances.2021004726)
- Robinson, A. J., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis. Oncotarget 12(10), pp. 952-954. (10.18632/oncotarget.27913)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193(1), pp. 155-159. (10.1111/bjh.17125)
- Robinson, A. J., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species and metabolic re-wiring in acute leukemias. In: Piccaluga, P. P. ed. Acute Leukemias. IntechOpen, pp. 35-56., (10.5772/intechopen.94829)
- Robinson, A. J., Davies, S., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species rewires metabolic activity in acute myeloid leukemia. Frontiers in Oncology 11, article number: 632623. (10.3389/fonc.2021.632623)
- Tonks, A. 2021. Make your cake and eat it: refueling of immune fitness in AML post allo-HCT using baking soda. Immunometabolism 3(1), article number: e210005. (10.20900/immunometab20210005)
2020
- Abate, W., Alrammah, H., Kiernan, M., Tonks, A. J. and Jackson, S. K. 2020. Lysophosphatidylcholine acyltransferase 2 (LPCAT2) co-localises with TLR4 and regulates macrophage inflammatory gene expression in response to LPS. Scientific Reports 10(1), article number: 10355. (10.1038/s41598-020-67000-x)
- Robinson, A. J. et al. 2020. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Research 80(5), pp. 937-949. (10.1158/0008-5472.CAN-19-1920)
- Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34(2), pp. 427-440. (10.1038/s41375-019-0596-4)
2019
- Menendez Gonzalez, J. B. et al. 2019. Gata2 as a crucial regulator of stem cells in adult hematopoiesis and acute myeloid leukemia. Stem Cell Reports 13(2), pp. 291-306. (10.1016/j.stemcr.2019.07.005)
- Morgan, R. G. et al. 2019. LEF-1 drives aberrant B-catenin nuclear localization in myeloid leukemia cells. Haematologica 104, pp. 1365-1377., article number: 202846. (10.3324/haematol.2018.202846)
2018
- Hassan, N., Ali, A., Withycombe, C., Ahluwalia, M., Al-Nasseri, R. H., Tonks, A. and Morris, K. 2018. TET-2 up-regulation is associated with the anti-inflammatory action of Vicenin-2. Cytokine 108, pp. 37-42. (10.1016/j.cyto.2018.03.016)
2015
- Munje, C., Hills, R. K., Whetton, A., Burnett, A. K., Darley, R. L. and Tonks, A. 2015. Cord blood-derived quiescent CD34+ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34+ cells. Gene Expression: International Journal of Molecular and Cellular Science 16(4), pp. 169-175. (10.3727/105221615X14399878166159)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29, pp. 1952-1954. (10.1038/leu.2015.62)
2014
- Morgan, R. G., Ridsdale, J., Tonks, A. and Darley, R. L. 2014. Factors affecting the nuclear localization of β-Catenin in normal and malignant tissue. Journal of Cellular Biochemistry 115(8), pp. 1351-1361. (10.1002/jcb.24803)
- Zabkiewicz, J., Pearn, L., Hills, R., Morgan, R. G., Tonks, A., Burnett, A. K. and Darley, R. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99(5), pp. 858-864. (10.3324/haematol.2013.096487)
2013
- Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122(19), pp. 3322-3330. (10.1182/blood-2013-04-491944)
- Morgan, R. G., Pearn, L., Liddiard, K., Pumford, S. L., Burnett, A. K., Tonks, A. and Darley, R. L. 2013. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia 27(2), pp. 336-343. (10.1038/leu.2012.221)
2012
- Daud, S. S. et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120(21), article number: 1281.
- Coles, S., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Man, S. T., Darley, R. L. and Tonks, A. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26(9), pp. 2146-2148. (10.1038/leu.2012.75)
- Coles, S., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Man, S. T., Darley, R. L. and Tonks, A. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26(9), pp. 2148-2151. (10.1038/leu.2012.77)
- Liddiard, K., Burnett, A. K., Darley, R. L. and Tonks, A. 2012. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1 [Letter]. Leukemia 26(1), pp. 177-179. (10.1038/leu.2011.188)
2011
- Coles, S., Man, S. T., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Darley, R. L. and Tonks, A. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135(S1), pp. 178. (10.1111/j.1365-2567.2011.03534.x)
- Coles, S., Wang, E. C. Y., Man, S. T., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25(5), pp. 792-799. (10.1038/leu.2011.1)
- Hole, P. S., Darley, R. L. and Tonks, A. 2011. Do reactive oxygen species play a role in myeloid leukemias?. Blood 117(22), pp. 5816-5826. (10.1182/blood-2011-01-326025)
2010
- Zabkiewicz, J., Pearn, L., Hills, R. K., Morgan, R. G., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116(21), pp. 892-893.
- Morgan, R. G., Pearn, L., Liddiard, K., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116(21), article number: 1573.
- Coles, S., Man, S. T., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116(21), pp. 218-218.
- Liddiard, K., Hills, R. K., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29(13), pp. 2005-2012. (10.1038/onc.2009.462)
- Hole, P. S., Pearn, L., Tonks, A. J., James, P. E., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 115(6), pp. 1238-1246. (10.1182/blood-2009-06-222869)
2008
- Morris, R. H. K., Tonks, A. J., Jones, K. P., Ahluwalia, M. K., Thomas, A. W., Tonks, A. and Jackson, S. K. 2008. DPPC regulates COX-2 expression in monocytes via phosphorylation of CREB. Biochemical and Biophysical Research Communications 370(1), pp. 174-178. (10.1016/j.bbrc.2008.03.052)
2007
- Tonks, A., Pearn, L., Musson, M., Gilkes, A. F., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21(12), pp. 2495-2505. (10.1038/sj.leu.2404961)
- Walsby, E. J., Gilkes, A. F., Tonks, A., Darley, R. L. and Mills, K. I. 2007. FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology 139(1), pp. 94-97. (10.1111/j.1365-2141.2007.06756.x)
- Tonks, A. J., Dudley, E., Porter, N. G., Parton, J., Brazier, J. S., Smith, E. L. and Tonks, A. 2007. A 5.8KDa component of manuka honey stimulates immune cells via TLR4. Journal of Leukocyte Biology 82(5), pp. 1147-1155. (10.1189/jlb.1106683)
- Tonks, A., Hills, R. K., White, P. C., Rosie, B., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
- Tonks, A., Hills, R. K., White, P. C., Rosie, B., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
2006
- Tonks, A., Pearn, L., Mills, K. I., Burnett, A. K. and Darley, R. L. 2006. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia 20(10), pp. 1883-5. (10.1038/sj.leu.2404364)
2005
- Tonks, A., Parton, J., Tonks, A. J., Morris, R. H. K., Finall, A., Jones, K. P. and Jackson, S. K. 2005. Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC. AJP Lung Cellular and Molecular Physiology 288(6), pp. 1070-80. (10.1152/ajplung.00386.2004)
- Tonks, A., Tonks, A. J., Pearn, L., Mohamad, Z., Burnett, A. K. and Darley, R. L. 2005. Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnology Progress 21(3), pp. 953-958. (10.1021/bp0500314)
2004
- Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18(7), pp. 1238-1245. (10.1038/sj.leu.2403396)
- Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18(7), pp. 1238-1245. (10.1038/sj.leu.2403396)
2003
- Tonks, A. et al. 2003. The AML-1 fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101(2), pp. 624-632. (10.1182/blood-2002-06-1732)
- Tonks, A. J., Tonks, A., Morris, R. H. K., Jones, K. P. and Jackson, S. K. 2003. Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl phosphatidylcholine. Journal of Leukocyte Biology 74(1), pp. 95-101. (10.1189/jlb.1202601)
- Tonks, A. et al. 2003. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101(2), pp. 624-632. (10.1182/blood-2002-06-1732)
Adrannau llyfrau
- Robinson, A. J., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species and metabolic re-wiring in acute leukemias. In: Piccaluga, P. P. ed. Acute Leukemias. IntechOpen, pp. 35-56., (10.5772/intechopen.94829)
Erthyglau
- Abdelfattah, A. et al. 2025. Impaired DNA damage responses and inflammatory signaling underpin hematopoietic stem cell defects in Gata2 haploinsufficiency. Stem Cell Reports 20(8), article number: 102596. (10.1016/j.stemcr.2025.102596)
- Rizzo, S., Varache, M., Sayers, E. J., Jones, A. T., Tonks, A., Thomas, D. W. and Ferguson, E. L. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19, pp. 5419-5437. (10.2147/IJN.S449185)
- Sorouri Khorashad, J., Rizzo, S. and Tonks, A. 2024. Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia. Cancer Drug Resistance 7, article number: 5. (10.20517/cdr.2023.125)
- Ullah, S. et al. 2023. Whole exome sequence of Pakistani acute lymphocytic leukemia patient from Pakhtuns ancestry reveal the novel genetic variant characterization in the GLDC gene. Journal of Biotechnology and Biomedicine 6(3), pp. 409-420. (10.26502/jbb.2642-91280103)
- Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37, pp. 276-287. (10.1038/s41375-022-01801-z)
- Wagstaff, M. et al. 2023. Crosstalk between β-catenin and WT1 signalling activity in acute myeloid leukemia [Letters to the Editor]. Haematologica 108(1) (10.3324/haematol.2021.280294)
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132(21), article number: e150750. (10.1172/JCI150750)
- Menezes, A. C. et al. 2022. Increased expression of RUNX3 inhibits normal human myeloid development. Leukemia 36, pp. 1769-1780. (10.1038/s41375-022-01577-2)
- Ullah, S., Tonks, A., Ullah Khan, A., Alruwaili, A. M. and lodhi, M. A. 2022. A Case report of rare disease Prolidase deficiency in a 15-year-old Pakistan boy. Journal of Rare Diseases Research & Treatment 7(2), pp. 1-4. (10.29245/2572-9411/2022/2.1206)
- Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12, article number: 840046. (10.3389/fonc.2022.840046)
- Hillier, J. et al. 2022. The BCAT1 CXXC motif provides protection against ROS in acute myeloid leukaemia cells. Antioxidants 11(4), article number: 683. (10.3390/antiox11040683)
- Menezes, A. C. et al. 2022. RUNX3 overexpression inhibits normal human erythroid development. Scientific Reports 12, article number: 1243. (10.1038/s41598-022-05371-z)
- Abdelfattah, A. M. et al. 2021. Gata2 haploinsufficiency promotes proliferation and functional decline of HSCs with myeloid bias during aging. Blood Advances 5(20), pp. 4285-4290. (10.1182/bloodadvances.2021004726)
- Robinson, A. J., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis. Oncotarget 12(10), pp. 952-954. (10.18632/oncotarget.27913)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193(1), pp. 155-159. (10.1111/bjh.17125)
- Robinson, A. J., Davies, S., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species rewires metabolic activity in acute myeloid leukemia. Frontiers in Oncology 11, article number: 632623. (10.3389/fonc.2021.632623)
- Tonks, A. 2021. Make your cake and eat it: refueling of immune fitness in AML post allo-HCT using baking soda. Immunometabolism 3(1), article number: e210005. (10.20900/immunometab20210005)
- Abate, W., Alrammah, H., Kiernan, M., Tonks, A. J. and Jackson, S. K. 2020. Lysophosphatidylcholine acyltransferase 2 (LPCAT2) co-localises with TLR4 and regulates macrophage inflammatory gene expression in response to LPS. Scientific Reports 10(1), article number: 10355. (10.1038/s41598-020-67000-x)
- Robinson, A. J. et al. 2020. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Research 80(5), pp. 937-949. (10.1158/0008-5472.CAN-19-1920)
- Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34(2), pp. 427-440. (10.1038/s41375-019-0596-4)
- Menendez Gonzalez, J. B. et al. 2019. Gata2 as a crucial regulator of stem cells in adult hematopoiesis and acute myeloid leukemia. Stem Cell Reports 13(2), pp. 291-306. (10.1016/j.stemcr.2019.07.005)
- Morgan, R. G. et al. 2019. LEF-1 drives aberrant B-catenin nuclear localization in myeloid leukemia cells. Haematologica 104, pp. 1365-1377., article number: 202846. (10.3324/haematol.2018.202846)
- Hassan, N., Ali, A., Withycombe, C., Ahluwalia, M., Al-Nasseri, R. H., Tonks, A. and Morris, K. 2018. TET-2 up-regulation is associated with the anti-inflammatory action of Vicenin-2. Cytokine 108, pp. 37-42. (10.1016/j.cyto.2018.03.016)
- Munje, C., Hills, R. K., Whetton, A., Burnett, A. K., Darley, R. L. and Tonks, A. 2015. Cord blood-derived quiescent CD34+ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34+ cells. Gene Expression: International Journal of Molecular and Cellular Science 16(4), pp. 169-175. (10.3727/105221615X14399878166159)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29, pp. 1952-1954. (10.1038/leu.2015.62)
- Morgan, R. G., Ridsdale, J., Tonks, A. and Darley, R. L. 2014. Factors affecting the nuclear localization of β-Catenin in normal and malignant tissue. Journal of Cellular Biochemistry 115(8), pp. 1351-1361. (10.1002/jcb.24803)
- Zabkiewicz, J., Pearn, L., Hills, R., Morgan, R. G., Tonks, A., Burnett, A. K. and Darley, R. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99(5), pp. 858-864. (10.3324/haematol.2013.096487)
- Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122(19), pp. 3322-3330. (10.1182/blood-2013-04-491944)
- Morgan, R. G., Pearn, L., Liddiard, K., Pumford, S. L., Burnett, A. K., Tonks, A. and Darley, R. L. 2013. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia 27(2), pp. 336-343. (10.1038/leu.2012.221)
- Daud, S. S. et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120(21), article number: 1281.
- Coles, S., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Man, S. T., Darley, R. L. and Tonks, A. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26(9), pp. 2146-2148. (10.1038/leu.2012.75)
- Coles, S., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Man, S. T., Darley, R. L. and Tonks, A. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26(9), pp. 2148-2151. (10.1038/leu.2012.77)
- Liddiard, K., Burnett, A. K., Darley, R. L. and Tonks, A. 2012. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1 [Letter]. Leukemia 26(1), pp. 177-179. (10.1038/leu.2011.188)
- Coles, S., Man, S. T., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Darley, R. L. and Tonks, A. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135(S1), pp. 178. (10.1111/j.1365-2567.2011.03534.x)
- Coles, S., Wang, E. C. Y., Man, S. T., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25(5), pp. 792-799. (10.1038/leu.2011.1)
- Hole, P. S., Darley, R. L. and Tonks, A. 2011. Do reactive oxygen species play a role in myeloid leukemias?. Blood 117(22), pp. 5816-5826. (10.1182/blood-2011-01-326025)
- Zabkiewicz, J., Pearn, L., Hills, R. K., Morgan, R. G., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116(21), pp. 892-893.
- Morgan, R. G., Pearn, L., Liddiard, K., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116(21), article number: 1573.
- Coles, S., Man, S. T., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116(21), pp. 218-218.
- Liddiard, K., Hills, R. K., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29(13), pp. 2005-2012. (10.1038/onc.2009.462)
- Hole, P. S., Pearn, L., Tonks, A. J., James, P. E., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 115(6), pp. 1238-1246. (10.1182/blood-2009-06-222869)
- Morris, R. H. K., Tonks, A. J., Jones, K. P., Ahluwalia, M. K., Thomas, A. W., Tonks, A. and Jackson, S. K. 2008. DPPC regulates COX-2 expression in monocytes via phosphorylation of CREB. Biochemical and Biophysical Research Communications 370(1), pp. 174-178. (10.1016/j.bbrc.2008.03.052)
- Tonks, A., Pearn, L., Musson, M., Gilkes, A. F., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21(12), pp. 2495-2505. (10.1038/sj.leu.2404961)
- Walsby, E. J., Gilkes, A. F., Tonks, A., Darley, R. L. and Mills, K. I. 2007. FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology 139(1), pp. 94-97. (10.1111/j.1365-2141.2007.06756.x)
- Tonks, A. J., Dudley, E., Porter, N. G., Parton, J., Brazier, J. S., Smith, E. L. and Tonks, A. 2007. A 5.8KDa component of manuka honey stimulates immune cells via TLR4. Journal of Leukocyte Biology 82(5), pp. 1147-1155. (10.1189/jlb.1106683)
- Tonks, A., Hills, R. K., White, P. C., Rosie, B., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
- Tonks, A., Hills, R. K., White, P. C., Rosie, B., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
- Tonks, A., Pearn, L., Mills, K. I., Burnett, A. K. and Darley, R. L. 2006. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia 20(10), pp. 1883-5. (10.1038/sj.leu.2404364)
- Tonks, A., Parton, J., Tonks, A. J., Morris, R. H. K., Finall, A., Jones, K. P. and Jackson, S. K. 2005. Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC. AJP Lung Cellular and Molecular Physiology 288(6), pp. 1070-80. (10.1152/ajplung.00386.2004)
- Tonks, A., Tonks, A. J., Pearn, L., Mohamad, Z., Burnett, A. K. and Darley, R. L. 2005. Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnology Progress 21(3), pp. 953-958. (10.1021/bp0500314)
- Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18(7), pp. 1238-1245. (10.1038/sj.leu.2403396)
- Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18(7), pp. 1238-1245. (10.1038/sj.leu.2403396)
- Tonks, A. et al. 2003. The AML-1 fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101(2), pp. 624-632. (10.1182/blood-2002-06-1732)
- Tonks, A. J., Tonks, A., Morris, R. H. K., Jones, K. P. and Jackson, S. K. 2003. Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl phosphatidylcholine. Journal of Leukocyte Biology 74(1), pp. 95-101. (10.1189/jlb.1202601)
- Tonks, A. et al. 2003. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101(2), pp. 624-632. (10.1182/blood-2002-06-1732)
Ymchwil
Trosolwg Ymchwil
Mae lewcemia myeloid acíwt (AML) yn dal i gael canlyniad gwael yn gyffredinol, yn enwedig i'r rhai dros chwe deg. Daw gobaith ar gyfer y dyfodol ar ffurf triniaethau sy'n targedu annormaleddau allweddol sy'n "sawdl Achilles" y clefyd; yn anffodus, mae AML yn glefyd amrywiol iawn a dim ond un is-fath o'r clefyd sy'n cael ei drin yn y modd hwn ar hyn o bryd. Rwy'n ymchwilio i rolau nifer o enynnau ymgeisydd gan gynnwys RUNX1::ETO, RUNX3, hnRNP, CD200, signalau Wnt, S100 a chynhyrchu rhywogaethau ocsigen adweithiol (ROS) mewn lewcamogenesis. Yn benodol, mae gen i ddiddordeb mewn sut mae'r broses o ddatblygiad haematopoietig mewn poblogaethau coesyn a progenitor yn cael ei dysreoleiddio gan y genynnau hyn mewn AML.
Disgrifiad Ymchwil
Mae trawsleoliadau sy'n effeithio ar y ffactor trawsgrifio RUNX1 ymhlith y rhai mwyaf cyffredin mewn AML a preleukaemia. Mae modelau knockout wedi dangos pwysigrwydd y genyn hwn ar gyfer datblygiad haematopoietig, fodd bynnag, ar hyn o bryd rydym yn deall ychydig o effaith genynnau RUNX1 wedi'u trawsleoli fel RUNX1::ETO ar ddatblygiad celloedd dynol cynradd. Nod ein hastudiaethau oedd cael dealltwriaeth fanwl o effaith RUNX1::ETO ar ddatblygiad celloedd cynradd dynol cyntefig. Rydym wedi cyflawni hyn trwy fynegi RUNX1::ETO yn ectopig yn CD34+ gan ddefnyddio fector retrofirysol sy'n cyd-fynegi protein fflwroleuol gwyrdd. Roedd hyn yn galluogi adnabod celloedd heintiedig mewn 'amser real', ac yn caniatáu inni astudio effeithiau RUNX1::ETO ar gelloedd cyntefig ac ar eu gallu dilynol i gwblhau eu gwahaniaethu i lawr y llinellau myeloid ac erythroid. Gan ddefnyddio'r dull hwn dangosom fod mynegiant RUNX1::ETO yn atal gwahaniaethu celloedd myeloid ac erythroid yn gryf yn ogystal â hyrwyddo eu hunan-adnewyddu. Rydym wedi defnyddio technoleg microarray wedyn i adnabod genynnau targed RUNX1::ETO. Ar hyn o bryd rydym yn ymchwilio i'r genynnau hyn a'u gallu i ailgrynhoi'r ffenoteip RUNX1::ETO.
Rydym hefyd wedi nodi annormaledd sy'n gyffredin i'r mwyafrif o gleifion AML, sef gor-gynhyrchu rhywogaethau ocsigen adweithiol (ROS). Er bod ROS yn niweidiol i gelloedd gwaed arferol, mae celloedd AML wedi datblygu ymwrthedd iddynt ac ar ben hynny maent yn dibynnu ar ROS i hyrwyddo eu twf. Ar hyn o bryd rydym yn ymchwilio i ddulliau a all fod yn effeithiol yn erbyn celloedd AML trwy ddefnyddio asiantau sy'n llawer haws eu goddef na chemotherapi confensiynol.
Mae gwybod pa enynnau, proteinau (a ROS) sy'n gysylltiedig â chynhyrchu gwaed annormal yn ein galluogi i ddatblygu triniaethau newydd sydd eu hangen yn hanfodol ar gyfer cleifion ag AML.
Grantiau a gynhaliwyd yn ystod y 5 mlynedd diwethaf
Ymchwil Gofal Iechyd Cymru. Ysgoloriaeth PhD sy'n pennu rôl NFIC mewn AML. Yr Athro Tonks (PI): Dr H WIlliams (Cyd-ap), Yr Athro Darley (Cyd-ap). 2022-2025; £66,000.
Canser y Gwaed yn y DU. Grant prosiect yn archwilio NOX2 fel elfen o therapi aml-darged ar gyfer myeloid acíwt. Yr Athro Tonks (PI): Dr Khorashad (Cyd-I), Yr Athro Darley (Cyd-ap). 2022-2025; £248,000.
Saudi Arabia Cenhadaeth Ddiwylliannol PhD Ysgoloriaeth. Rôl proteinau hnRNP mewn lewcaemogenesis. Ysgoloriaeth PhD. Yr Athro Tonks (PI), Yr Athro Darley (Cyd-ap). 2021-2025: £146,000.
Saudi Arabia Cenhadaeth Ddiwylliannol PhD Ysgoloriaeth. Adnabod a dilysu targedau therapiwtig a biofarcwyr newydd mewn lewcemia myeloid acíwt. Yr Athro Darley (PI), Yr Athro Tonks (Cyd-ap). 2021-2025: £142,000.
Gwobr cychwyn cychwyn trosiadol Wellcome ISSF. Cyfieithiad PFKFB3 yn AML. ↑ A Tonks (PI), R Darley, S Knaper (Co-app). 2020-2021. £37,645.
Gwobr cychwyn cychwyn trosiadol Wellcome ISSF. Sgrinio gweithgaredd gwrthganser therapiwteg polymer gwrthfiotigol newydd. (Elain Ferguson PI, A Tonks, Cyd-ap a Chyd-ap Arwyn Jones). 2019-2020. £49,645.
Ysgoloriaeth PhD. Rôl signalau Wnt yn natblygiad bôn-gelloedd gwaed ac mewn lewcemia myeloid acíwt Yr Athro Darley (PI), Dr Tonks (Co-app). 2018-2021: £75,000.
Ysgoloriaeth PhD. Rôl Protein Kinase C Epsilon yn Pathogenesis ac Ymwrthedd Triniaeth Lewcemia Myeloid Acíwt. Yr Athro Darley (PI), Dr Tonks (Cyd-ap). 2017-2020: £75,000.
Ysgoloriaeth PhD. Defnyddio Sbectrometreg Màs iTRAQ i nodi'r mecanwaith o aflonyddwch datblygiadol a achosir gan RUNX1-ETO. Dr Tonks (PI), Yr Athro Darley (Cyd-ap). 2017-2020: £75,000
Ymchwil Canser Cymru: Ysgoloriaeth PhD. Rôl Runx3 mewn lewcaemogenesis. Dr Tonks (PI), Yr Athro Darley (Cyd-ap). 2017-2020: £109,301.
Addysgu
- Rwy'n Gymrawd o'r Higher Education Acadamy.
- Rwy'n cyfrannu at addysgu sy'n gysylltiedig â sawl cwrs a modiwl ar draws yr Ysgol a'r Colegau ym Mhrifysgol Caerdydd.
- Rwy'n darparu sawl prosiect labordy ar gyfer myfyrwyr israddedig, ôl-raddedig, MRes a PTY i hyfforddi yn fy labordy.
- Rwy'n ddarlithydd allanol ar gyfer sawl prifysgol yn y DU ac yn siaradwr gwadd yn rhyngwladol.
- Rwy'n arholwr allanol i fyfyrwyr PGR.
- Rwy'n arholwr allanol ar gyfer cyrsiau BSc/MSi.
Bywgraffiad
Education and significant professional training courses
2014: Fellow of the Higher Education Academy
2012-2014: ILM endorsed course for Practical Leadership for University Management, Cardiff University, Cardiff, UK
2012-2013: CPD in Medical Education Orientation Programme, School of Medicine, Cardiff University, Cardiff UK
1997-2000: PhD – Pulmonary immunology/ROS, Cardiff University / University of Wales Institute Cardiff (UWIC)
1996: HPC Registration for Biomedical Sciences, Health Professions Council, UK
1993-1997: BSc (Hons) Biomedical Sciences (Ist Class), UWIC, Cardiff, UK
Career Overview
**Present - Senior Lecturer, Department of Haematology, Cardiff University, UK
2003-2009 - Lecturer, Department of Haematology, Cardiff University, UK
2000-2003 - Post-doctoral Research Fellow, Department of Haematology, Cardiff University, UK
2000-2002 - Part time Lecturer, School of Applied Sciences, UWIC, Cardiff, UK
1997-2000 - Research Assistant, School of Applied Sciences, UWIC, Cardiff, UK
1995-1996, 1997 - Biomedical Scientist, Royal Gwent Hospital, Pathology Department, Newport, UK
Aelodaethau proffesiynol
- Rwy'n Gymrawd yr Academi Addysg Uwch (2014).
Safleoedd academaidd blaenorol
Trosolwg o'r Gyrfa
2024 - Presennol - Pennaeth Dros Dro yr Adran Haematoleg, Prifysgol Caerdydd, y DU
2020- Presennol - Athro mewn Haematoleg, Adran Haematoleg, Prifysgol Caerdydd, DU
2016-2020 - Darllenydd, Adran Haematoleg, Prifysgol Caerdydd , DU
2009-2016 -Darlithydd S enior , Adran Haematoleg, Prifysgol Caerdydd, DU
2003-2009 - Darlithydd , Adran Haematoleg, Prifysgol Caerdydd, DU
2000-2003 - Cymrawd Ymchwil Ôl-ddoethurol , Adran Haematoleg, Prifysgol Caerdydd, y DU
2000-2002 - Darlithydd Rhan Amser , Ysgol y Gwyddorau Cymhwysol, UWIC, Caerdydd, DU
1997-2000 - Cynorthwyydd Ymchwil , Ysgol y Gwyddorau Cymhwysol, UWIC, Caerdydd, y DU
1995-1996, 1997 - Gwyddonydd Biofeddygol , Ysbyty Brenhinol Gwent, Adran Patholeg, Casnewydd, DU
Pwyllgorau ac adolygu
| Grantiau | Gweithgaredd Diwethaf | Statws |
| BBSRC (Panel C) | 2023 | Aelod o'r Panel |
| Cartref | 2023 | Adolygwr |
| Canser y Gwaed yn y DU | 2024 | Adolygwr |
| Lewcemia y DU | 2024 | Adolygwr |
| HCRW (HRA) | 2023 | Aelod o'r Panel |
| BBSRC (Panel D) | 2022 | Aelod o'r Panel |
| Swyddi | 2022 | Adolygwr |
| MRC (Cymrodorion) | 2024 | Adolygwr |
| Ymchwil Canser y Gogledd Orllewin | 2024 | Adolygwr |
| HCRW (Panel Cymrodoriaeth) | 2022 | Aelod o'r Panel |
| Y Gymdeithas Frenhinol | 2022 | Adolygwr |
| Lewcemia y DU | 2024 | Aelod o'r Panel |
| Elusen Barts | 2022 | Adolygwr |
| Prifysgol Sharjah, Emiradau Arabaidd Unedig | 2022 | Adolygwr |
| Sganio plant | 2021 | Adolygwr |
| MRC (MCMB) | 2021 | Adolygwr |
| PSG | 2021 | Adolygwr |
| Plant â Leuka | 2024 | Adolygwr |
| Plant C a LG | 2024 | Adolygwr |
| Cartref | 2021 | Adolygwr |
| Cronfa Wyddoniaeth y Swistir | 2021 | Adolygwr |
| Ymddiriedolaeth Wellcome | 2021 | Adolygwr |
| HCRW (AWPP) | 2021 | Aelod o'r Panel |
| Newyddion | 2020 | Adolygwr |
| LLNI | 2019 | Adolygwr |
| Coed Rhosod | 2019 | Adolygwr |
| ERC | 2024 | Adolygwr |
| JGW Patterson | 2017 | Adolygwr |
| NCR3 | 2013 | Adolygwr |
| Cyngor RG HK | 2013 | Adolygwr |
| Cartref | 2012 | Adolygwr |
| Cartref | 2012 | Adolygwr |
| Cymdeithas Ddynol | 2012 | Adolygwr |
| Enid George | 2010 | Adolygwr |
| Ymddiriedolaeth Ymchwil Gogledd Cymru | 2005 | Adolygwr |
Meysydd goruchwyliaeth
Mae gen i hanes ymchwil sy'n canolbwyntio ar ddeall sut mae annormaleddau moleciwlaidd sy'n gysylltiedig â lewcemia yn cyfrannu at pathogenesis y cyflyrau hyn. Rwy'n fentor profiadol gyda record goruchwylio PGR llwyddiannus rhagorol, gan gynnwys datblygiad ECR. Rwyf wedi goruchwylio dros 15 o fyfyrwyr PGR i'w cwblhau'n olynol. Ar hyn o bryd rwy'n goruchwylio wyth myfyriwr PhD.
Roeddwn yn flaenorol yn Gyfarwyddwr / arweinydd PGR Rhanbarthol (~ 10y) sy'n gyfrifol am fonitro cynnydd ac amgylchedd PGR ~ 45 o fyfyrwyr ar draws pob blwyddyn o astudio o fewn fy Divsion. Dros yr 20 mlynedd diwethaf rwyf wedi goruchwylio nifer o fyfyrwyr BSc meddygol / ffarmacolegol, graddau rhyngwynebol BSc Meddygol a myfyrwyr MPhil / MSc / MRes. Rwyf wedi bod yn arholwr mewnol/allanol neu'n gadeirydd arholiadau viva voce ar sawl achlysur. Mae fy enw da rhyngwladol yn y maes hwn yn cael ei dystio gan archwiliadau allanol yn y DU ac Ewrop.
Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PGR ym meysydd
- Malaenrwydd haematolegol
- Therapïau wedi'u targedu a meddygaeth fanwl mewn canser y gwaed
- Straen ocsideiddiol a signalau REDOX mewn canser
Goruchwyliaeth gyfredol
Maryam Alanazi
Maryam Ahmed Halawi Halawi
Owen Hughes
Abdulsalam Alruwaili
Contact Details
TonksA@caerdydd.ac.uk
+44 29207 42235
Prif Adeilad yr Ysbyty, Llawr 7, Ystafell 187, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29207 42235
Prif Adeilad yr Ysbyty, Llawr 7, Ystafell 187, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Themâu ymchwil
Arbenigeddau
- cancr
- Tiwmorau haematolegol